Cargando…

Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma

Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus-associated non-Hodgkin lymphoma linked to an aggressive clinical course and poor prognosis. Despite an improvement in survival outcomes with the incorporation of novel agents including immune checkpoint inhibitors in the treatment of NK...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Jason Yongsheng, Lim, Jing Quan, Ong, Choon Kiat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398475/
https://www.ncbi.nlm.nih.gov/pubmed/34440582
http://dx.doi.org/10.3390/life11080838
_version_ 1783744849057415168
author Chan, Jason Yongsheng
Lim, Jing Quan
Ong, Choon Kiat
author_facet Chan, Jason Yongsheng
Lim, Jing Quan
Ong, Choon Kiat
author_sort Chan, Jason Yongsheng
collection PubMed
description Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus-associated non-Hodgkin lymphoma linked to an aggressive clinical course and poor prognosis. Despite an improvement in survival outcomes with the incorporation of novel agents including immune checkpoint inhibitors in the treatment of NKTCL, a significant proportion of patients still relapse or remain refractory to treatment. Several clinical prognostic models have been developed for NKTCL patients treated in the modern era, though the optimal approach to risk stratification remains to be determined. Novel molecular biomarkers derived from multi-omic profiling have recently been developed, with the potential to improve diagnosis, prognostication and treatment of this disease. Notably, a number of potential biomarkers have emerged from a better understanding of the tumor immune microenvironment and inflammatory responses. This includes a recently described 3′UTR structural variant in the PD-L1 gene, which confers susceptibility to checkpoint immunotherapy. In this review, we summarize the biomarker landscape of NKTCL and highlight emerging biomarkers with the potential for clinical implementation.
format Online
Article
Text
id pubmed-8398475
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83984752021-08-29 Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma Chan, Jason Yongsheng Lim, Jing Quan Ong, Choon Kiat Life (Basel) Review Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus-associated non-Hodgkin lymphoma linked to an aggressive clinical course and poor prognosis. Despite an improvement in survival outcomes with the incorporation of novel agents including immune checkpoint inhibitors in the treatment of NKTCL, a significant proportion of patients still relapse or remain refractory to treatment. Several clinical prognostic models have been developed for NKTCL patients treated in the modern era, though the optimal approach to risk stratification remains to be determined. Novel molecular biomarkers derived from multi-omic profiling have recently been developed, with the potential to improve diagnosis, prognostication and treatment of this disease. Notably, a number of potential biomarkers have emerged from a better understanding of the tumor immune microenvironment and inflammatory responses. This includes a recently described 3′UTR structural variant in the PD-L1 gene, which confers susceptibility to checkpoint immunotherapy. In this review, we summarize the biomarker landscape of NKTCL and highlight emerging biomarkers with the potential for clinical implementation. MDPI 2021-08-16 /pmc/articles/PMC8398475/ /pubmed/34440582 http://dx.doi.org/10.3390/life11080838 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chan, Jason Yongsheng
Lim, Jing Quan
Ong, Choon Kiat
Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma
title Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma
title_full Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma
title_fullStr Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma
title_full_unstemmed Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma
title_short Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma
title_sort towards next generation biomarkers in natural killer/t-cell lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398475/
https://www.ncbi.nlm.nih.gov/pubmed/34440582
http://dx.doi.org/10.3390/life11080838
work_keys_str_mv AT chanjasonyongsheng towardsnextgenerationbiomarkersinnaturalkillertcelllymphoma
AT limjingquan towardsnextgenerationbiomarkersinnaturalkillertcelllymphoma
AT ongchoonkiat towardsnextgenerationbiomarkersinnaturalkillertcelllymphoma